SciCombinator

Discover the most talked about and latest scientific content & concepts.

PW Andrews, A Bharwani, KR Lee, M Fox and JA Thomson
Abstract
The role of serotonin in depression and antidepressant treatment remains unresolved despite decades of research. In this paper, we make three major claims. First, serotonin transmission is elevated in multiple depressive phenotypes, including melancholia, a subtype associated with sustained cognition. The primary challenge to this first claim is that the direct pharmacological effect of most symptom-reducing medications, such as the selective serotonin reuptake inhibitors (SSRIs), is to increase synaptic serotonin. The second claim, which is crucial to resolving this paradox, is that the serotonergic system evolved to regulate energy. By increasing extracellular serotonin, SSRIs disrupt energy homeostasis and often worsen symptoms during acute treatment. Our third claim is that symptom reduction is not achieved by the direct pharmacological properties of SSRIs, but by the brain’s compensatory responses that attempt to restore energy homeostasis. These responses take several weeks to develop, which explains why SSRIs have a therapeutic delay. We demonstrate the utility of our claims by examining what happens in animal models of melancholia and during acute and chronic SSRI treatment.
Tweets*
134
Facebook likes*
21
Reddit*
5
News coverage*
4
Blogs*
11
SC clicks
1
Concepts
Paroxetine, Antidepressant, Tricyclic antidepressant, Fluoxetine, Sertraline, Major depressive disorder, Serotonin, Selective serotonin reuptake inhibitor
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com